Artrya (AYA) H2 2025 earnings summary

Executive summary

• Transitioned from development to commercial operations, securing FDA clearance for SalixⓇ Coronary Anatomy and Plaque modules, enabling U.S. market entry and commercial deployment.

• Achieved first U.S. commercial revenues via a five-year, $0.6M contract with Tanner Health and established partnerships with Northeast Georgia Health System and Cone Health.

• Raised $20M during the year and $80M post-period to accelerate U.S. commercialization and product development.

• Leadership transition with John Konstantopoulos appointed CEO and Bernie Ridgeway as Executive Chair.

Financial highlights

• Revenue: $5.46M (2025), up from $3.69M (2024).

• Net loss: $16.41M (2025), compared to $14.00M (2024).

• Cash balance: $11.3M at year-end, up from $7.1M in 2024.

• Net assets increased to $21.3M from $16.8M year-over-year.

• No dividends declared or paid.

Outlook and guidance

• Focus on securing FDA clearance for SalixⓇ Coronary Flow module in early 2026.

• Plans to expand commercial rollout in the U.S. and Australia, targeting additional hospital integrations and revenue growth.

• SAPPHIRE study to drive clinical validation and conversion of research partners into commercial customers.